Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease

Blood

Volumn 126, Issue 20, 2015, Pages 2320-2328

  Carbonare, Luca Dalle ^a   Matte', Alessandro ^a   Valenti, Maria Teresa ^a   Siciliano, Angela ^a   Mori, Antonio ^a   Schweiger, Vittorio ^a   Zampieri, Gino ^b   Perbellini, Luigi ^c   De Franceschi, Lucia ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b Advanced Consulting Engineering AC and e   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CATALASE; CATHEPSIN K; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEONECTIN; PEROXIREDOXIN 2; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CTSK PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; RUNX2 PROTEIN, MOUSE; SPARC PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ARTICLE; BONE DISEASE; BONE MASS; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; HYPOXIA; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION; SICKLE CELL ANEMIA; SICKLE CELL BONE DISEASE; UPREGULATION; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REPERFUSION INJURY; TRANSGENIC MOUSE;

ANEMIA, SICKLE CELL; ANIMALS; BONE DISEASES; CATHEPSIN K; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; OSTEOCLASTS; OSTEONECTIN; RANK LIGAND; REPERFUSION INJURY;

EID: 84948958941     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-641969     Document Type: Article

References (48)

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6): 480-487.
2. Murray CJ, Vos T, Lozano R, et al. Disabilityadjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-2223.
3. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704-712.
4. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011;37(3):226-236.
5. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63-279.
6. De Franceschi L, Corrocher R. Established and experimental treatments for sickle cell disease. Haematologica. 2004;89(3):348-356.
7. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79(8):2154-2163.
8. Vinchi F, De Franceschi L, Ghigo A, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127(12):1317-1329.
9. Hebbel RP, Vercellotti G, Nath KA. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemoprophylaxsis. Cardiovasc Hematol Disord Drug Targets. 2009;9(4):271-292.
10. Hebbel RP. Adhesion of sickle red cells to endothelium: myths and future directions. Transfus Clin Biol. 2008;15(1-2):14-18.
11. Platt OS. The acute chest syndrome of sickle cell disease. N Engl J Med. 2000;342(25):1904-1907.
12. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol. 2005;129(4):482-490.
13. Osunkwo I. An update on the recent literature on sickle cell bone disease. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):539-546.
14. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer. 2006;47(7):901-906.
15. Dalle Carbonare L, Innamorati G, Valenti MT. Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell Rev. 2012; 8(3):891-897.
16. Bruzzaniti A, Baron R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 2006;7(1-2):123-139.
17. Kalish BT, Matte A, Andolfo I, et al. Dietary v-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica. 2015;100(7):870-880.
18. Akinsanmi IA LA, Gulberg R, Platt M, Barabino G. Age and sex determinats of bone phenotype in a transgenic mouse model of sickle cell disease [abstract]. Blood. 2012;120(21). Abstract 3249.
19. Siciliano A, Malpeli G, Platt OS, et al. Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. Haematologica. 2011;96(1):24-32.
20. De Franceschi L, Platt OS, Malpeli G, et al. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J. 2008;22(6):1849-1860.
21. Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118(5):1924-1933.
22. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003;101(6):2412-2418.
23. Vegger JB, Nielsen ES, Brüel A, Thomsen JS. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats. Bone. 2014;66:287-295.
24. Sehitoglu I, Tumkaya L, Bedir R, et al. Zoledronic acid aggravates kidney damage during ischemia reperfusion injury in rat. J Environ Pathol Toxicol Oncol. 2015;34(1):53-61.
25. Liu J, Zhang J, Ginzburg Y, et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood. 2013;121(8):e43-e49.
26. Franco SS, De Falco L, Ghaffari S, et al. Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica. 2014; 99(2):267-275.
27. Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf. 2010;2: 121-137.
28. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16(1): 97-103.
29. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28(1):2-17.
30. Valenti MT, Giannini S, Donatelli L, et al. The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163.
31. Garrahan NJ, Mellish RW, Compston JE. A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J Microsc. 1986;142(Pt 3):341-349.
32. Compston JE, Mellish RW, Garrahan NJ. Age-related changes in iliac crest trabecular microanatomic bone structure in man. Bone. 1987;8(5):289-292.
33. Vesterby A, Gundersen HJ, Melsen F. Star volume of marrow space and trabeculae of the first lumbar vertebra: sampling efficiency and biological variation. Bone. 1989;10(1):7-13.
34. Valenti MT, Zanatta M, Donatelli L, et al. Ascorbic acid induces either differentiation or apoptosis in MG-63 osteosarcoma lineage. Anticancer Res. 2014;34(4):1617-1627.
35. Xiao G, Cheng H, Cao H, et al. Critical role of filamin-binding LIM protein 1 (FBLP-1)/migfilin in regulation of bone remodeling. J Biol Chem. 2012; 287(25):21450-21460.
36. Mantila Roosa SM, Liu Y, Turner CH. Gene expression patterns in bone following mechanical loading. J Bone Miner Res. 2011;26(1):100-112.
37. Valenti MT, Garbin U, Pasini A, et al. Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARg2 expression in MSCs-like of osteoporotic patients. PLoS One. 2011;6(6):e20363.
38. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145(10):3297-3303.
39. Rifas L, Weitzmann MN. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum. 2009;60(11):3324-3335.
40. Bartell SM, Kim HN, Ambrogini E, et al. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014;5:3773.
41. Park H, Noh AL, Kang JH, Sim JS, Lee DS, Yim M. Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3. Antioxid Redox Signal. 2015;22(1):63-77.
42. Terpos E, Viniou N, de la Fuente J, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol. 2003;70(1):34-42.
43. Nouraie M, Cheng K, Niu X, et al. Predictors of osteoclast activity in patients with sickle cell disease. Haematologica. 2011;96(8):1092-1098.
44. Neves FS, Oliveira LS, Torres MG, et al. Evaluation of panoramic radiomorphometric indices related to low bone density in sickle cell disease. Osteoporos Int. 2012;23(7):2037-2042.
45. Nur E, Mairuhu W, Biemond BJ, et al; CURAMA study group. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. Am J Hematol. 2010;85(11): 902-904.
46. Sarrai M, Duroseau H, D'Augustine J, Moktan S, Bellevue R. Bone mass density in adults with sickle cell disease. Br J Haematol. 2007;136(4): 666-672.
47. Miller RG, Segal JB, Ashar BH, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006;81(4):236-241.
48. Ebert R, Zeck S, Krug R, et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone. 2009;44(5):858-864.